Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fingolimod with probiotic and/or vitamin E for liver complications in relapsing-remitting multiple sclerosis
IRCT20120215009014N335Phase 2Completed
- Sponsor
- Hamadan University of Medical Sciences
- Start
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of fingolimod in multiple sclerosis (MS) (4 arms), sponsored by Hamadan University of Medical Sciences. Primary endpoint: Hepatic complication. Started Apr 2020; status: completed.
02
Drugs
fingolimod
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on IRCT20120215009014N335.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20120215009014N335.